Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The Conversation

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

The New Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

Evening Standard

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The National (Scotland)

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

The Independent UK

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug found

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Daily Record

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

The Independent UK

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Barchart

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

WEKU

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

The Guardian - UK

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Axios

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Chicago Sun-Times

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

Inverse

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

Miami Herald

$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine

Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Editorial: What insulin should cost: Eli Lilly comes through for Americans with diabetes

A hearty thank you to Eli Lilly, one of the planet’s top three producers of insulin, for slashing the price of its most widely prescribed form of insulin by 70% while capping related out-of-pocket costs at $35 a month. That means diabetics with private insurance will now pay costs on…

Tribune News Service

Commentary: Want to make drugs, including insulin, affordable? End patent abuse

Drugmaker Eli Lilly on Wednesday said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare’s prescription drug program, which also maintains a $35 cap. The welcome move comes as lawmakers in both major parties…

The Independent UK

Reporter behind viral Eli Lilly parody account peels back curtain on ‘stupid little tweet’ that helped trigger insulin price cap

Reporter Sean Morrow wants to make sure credit goes to lawmakers working on drug pricing, Graig Graziosi reports

The Conversation

Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies…

The Independent UK

‘Hero’ journalist congratulated after Eli Lilly lowers price of insulin after his spoof tweet raised awareness

Eli Lilly’s CEO challenged other pharmaceutical companies to drop insulin prices as well

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

Tribune News Service

Eli Lilly is capping consumer insulin costs at $35

Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations